# ADC Therapeutics Raises $86.6 Million

> ADC Therapeutics secures $86.6 million to extend cash runway to 2029.
- Title: ADC Therapeutics Raises $86.6 Million · Pulse 2.0 | Shortify
- Summary: ADC Therapeutics secures $86.6 million to extend cash runway to 2029. ADC Therapeutics raised $86.6 million to extend cash runway into 2029.
- Keywords: adc therapeutics, zynlonta, healthcare royalty, senior secured loan, bain capital life sciences, redmile, tcgx, nantahala capital, pipe, phase 3 trials, diffuse large b-cell lymphoma, marginal zone lymphoma
- Source: Pulse 2.0 — https://pulse2.com/adc-therapeutics-raises-86-6-million-and-restructures-debt-to-extend-cash-runway-into-2029
- Author: Amit Chowdhry
- Published: 2026-10-09T21:45:00+00:00
- Read time: 1 min
- Topics: adc therapeutics, zynlonta, healthcare royalty, senior secured loan, bain capital life sciences, redmile, tcgx, nantahala capital, pipe, phase 3 trials, diffuse large b-cell lymphoma, marginal zone lymphoma
## Financial Restructuring Announced
ADC Therapeutics announced a comprehensive financial restructuring including an $86.6 million private placement and loan refinancing.
## Private Placement Details
The $86.6 million private investment includes 12.9 million common shares priced at $1.42 per share.
## Pre-Funded Warrants
ADC Therapeutics sells pre-funded warrants to purchase 48.1 million common shares at $1.32 per warrant.
## PIPE Closing Date
The PIPE is expected to close on October 22, 2026, subject to customary closing conditions.
## ZYNLONTA Development
ADC Therapeutics plans to use funds for ZYNLONTA Phase 3 trials in diffuse large B-cell lymphoma and marginal zone lymphoma.
## Healthcare Royalty Amendment
Healthcare Royalty amended agreement eliminates $150 million payment and reduces third-party indebtedness to $50 million.
## Key takeaway

ADC Therapeutics raised $86.6 million to extend cash runway into 2029.